AZ and Merck's Lynparza meets in Phase III for first-line ovarian cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib as a first-line maintenance therapy improved

Read the full 204 word article

User Sign In